Circulating miRNAs appear promising therapeutic and prognostic biomarkers. We aimed to investigate the predictive value of circulating miRNAs on the disease outcome following anti-TNF therapy in patients with ankylosing spondylitis (AS). Our study included 19 AS patients assessed at baseline (M0), after three (M3) and twelve months (M12) of therapy. Total RNA was isolated from plasma. A comprehensive analysis of 380 miRNAs using TaqMan Low Density Array (TLDA) was followed by a single assay validation of selected miRNAs. All AS patients had high baseline disease activity and an excellent response to anti-TNF therapy at M3 and M12. TLDA analysis revealed the dysregulation of 17 circulating miRNAs, including miR-145. Single assay validation confirmed that miR-145 is significantly downregulated at M3 compared to baseline. The decrease in the levels of miR-145 from M0 to M3 negatively correlated with the change in BASDAI from M0 to M3; and positively correlated with disease activity improvement from M3 to M12 as per BASDAI and ASDAS. The predictive value of the early change in miR-145 and levels of miR-145 at M3 were further validated by Receiver operating curves analysis. We show thatthe early change in circulating miR-145 may be a predictor for the future outcome ofAS patients treated with TNF inhibitors. Patients with a more significant decrease in miR-145 levels may show further significant improvement of disease activity after 12 months. Monitoring the expression of miR-145 in plasma in AS patients may, therefore, influence our therapeutic decision-making.

Institute of Rheumatology Prague Czech Republic

Zobrazit více v PubMed

BRANDT J, HAIBEL H, CORNELY D, GOLDER W, GONZALEZ J, REDDIG J, THRIENE W, SIEPER J, BRAUN J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. PubMed DOI

BRAUN J, Van Der HEIJDE D, DOUGADOS M, EMERY P, KHAN MA, SIEPER J, Van Der LINDEN S. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis. 2002;61(Suppl 3):iii9–iii23. doi: 10.1136/ard.61.suppl_3.iii19. PubMed DOI PMC

CASTRO-VILLEGAS C, PEREZ-SANCHEZ C, ESCUDERO A, FILIPESCU I, VERDU M, RUIZ-LIMON P, AGUIRRE MA, JIMENEZ-GOMEZ Y, FONT P, RODRIGUEZ-ARIZA A, PEINADO JR, COLLANTES-ESTEVEZ E, GONZALEZ-CONEJERO R, MARTINEZ C, BARBARROJA N, LOPEZ-PEDRERA C. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res Ther. 2015;17:49. doi: 10.1186/s13075-015-0555-z. PubMed DOI PMC

CICI D, CORRADO A, ROTONDO C, CANTATORE FP. Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis. Int J Mol Sci. 2019;20:5552. doi: 10.3390/ijms20225552. PubMed DOI PMC

CIECHOMSKA M, BONEK K, MERDAS M, ZARECKI P, SWIERKOT J, GLUSZKO P, BOGUNIA-KUBIK K, MASLINSKI W. Changes in MiRNA-5196 Expression as a potential biomarker of anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis patients. Arch Immunol Ther Exp (Warsz) 2018;66:389–397. doi: 10.1007/s00005-018-0513-y. PubMed DOI PMC

CORTEZ MA, BUESO-RAMOS C, FERDIN J, LOPEZ-BERESTEIN G, SOOD AK, CALIN GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Onco. 2011;8:467–477. doi: 10.1038/nrclinonc.2011.76. PubMed DOI PMC

DLOUHA D, HUBACEK JA. Regulatory RNAs and cardiovascular disease - with a special focus on circulating microRNAs. Physiol Res. 2017;66:S21–S38. doi: 10.33549/physiolres.933588. PubMed DOI

FAN L, WU Q, XING X, WEI Y, SHAO Z. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai) 2012;44:407–414. doi: 10.1093/abbs/gms019. PubMed DOI

FILKOVA M, ARADI B, SENOLT L, OSPELT C, VETTORI S, MANN H, FILER A, RAZA K, BUCKLEY CD, SNOW M, VENCOVSKY J, PAVELKA K, MICHEL BA, GAY RE, GAY S, JUNGEL A. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis. 2014;73:1898–1904. doi: 10.1136/annrheumdis-2012-202815. PubMed DOI PMC

FILKOVA M, JUNGEL A, GAY RE, GAY S. MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy. BioDrugs. 2012;26:131–141. doi: 10.2165/11631480-000000000-00000. PubMed DOI

FUKUDA T, OCHI H, SUNAMURA S, HAIDEN A, BANDO W, INOSE H, OKAWA A, ASOU Y, TAKEDA S. MicroRNA-145 regulates osteoblastic differentiation by targeting the transcription factor Cbfb. FEBS Lett. 2015;589:3302–3308. doi: 10.1016/j.febslet.2015.09.024. PubMed DOI

GARRETT S, JENKINSON T, KENNEDY LG, WHITELOCK H, GAISFORD P, CALIN A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–2291. PubMed

HAO W, LIU H, ZHOU L, SUN Y, SU H, NI J, HE T, SHI P, WANG X. MiR-145 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells through targeting FoxO1. Exp Biol Med (Maywood) 2018;243:386–393. doi: 10.1177/1535370217746611. PubMed DOI PMC

HAROON N, INMAN RD, LEARCH TJ, WEISMAN MH, LEE M, RAHBAR MH, WARD MM, REVEILLE JD, GENSLER LS. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–2654. doi: 10.1002/art.38070. PubMed DOI PMC

HRUSKOVA V, JANDOVA R, VERNEROVA L, MANN H, PECHA O, PRAJZLEROVA K, PAVELKA K, VENCOVSKY J, FILKOVA M, SENOLT L. MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis. Arthritis Res Ther. 2016;18:124. doi: 10.1186/s13075-016-1023-0. PubMed DOI PMC

HU K, OLSEN BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone. 2016;91:30–38. doi: 10.1016/j.bone.2016.06.013. PubMed DOI PMC

CHEN Y, WANG X, YANG M, RUAN W, WEI W, GU D, WANG J, GUO X, GUO L, YUAN Y. miR-145-5p increases osteoclast numbers in vitro and aggravates bone erosion in collagen-induced arthritis by targeting osteoprotegerin. Med Sci Monit. 2018;24:5292–5300. doi: 10.12659/MSM.908219. PubMed DOI PMC

JIA J, TIAN Q, LING S, LIU Y, YANG S, SHAO Z. miR-145 suppresses osteogenic differentiation by targeting Sp7. FEBS Lett. 2013;587:3027–3031. doi: 10.1016/j.febslet.2013.07.030. PubMed DOI

LUKAS C, LANDEWE R, SIEPER J, DOUGADOS M, DAVIS J, BRAUN J, Van Der LINDEN S, Van Der HEIJDE D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18–24. doi: 10.1136/ard.2008.094870. PubMed DOI

LV Q, LI Q, ZHANG P, JIANG Y, WANG X, WEI Q, CAO S, LIAO Z, LIN Z, PAN Y, HUANG J, LI T, JIN O, WU Y, GU J. Disorders of microRNAs in peripheral blood mononuclear cells: as novel biomarkers of ankylosing spondylitis and provocative therapeutic targets. Biomed Res Int. 2015;2015:504208. doi: 10.1155/2015/504208. PubMed DOI PMC

MACHADO P, LANDEWE R, BRAUN J, HERMANN KG, BAKER D, Van Der HEIJDE D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis. 2010;69:1465–1470. doi: 10.1136/ard.2009.124206. PubMed DOI

PEDERSEN SJ, HETLAND ML, SORENSEN IJ, OSTERGAARD M, NIELSEN HJ, JOHANSEN JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol. 2010;29:1301–1309. doi: 10.1007/s10067-010-1528-x. PubMed DOI

PRAJZLEROVA K, GROBELNA K, HUSAKOVA M, FOREJTOVA S, JUNGEL A, GAY S, VENCOVSKY J, PAVELKA K, SENOLT L, FILKOVA M. Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis. PLoS One. 2017;12:e0185323. doi: 10.1371/journal.pone.0185323. PubMed DOI PMC

PRAJZLEROVA K, GROBELNA K, PAVELKA K, SENOLT L, FILKOVA M. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016;15:501–509. doi: 10.1016/j.autrev.2016.02.002. PubMed DOI

RUDWALEIT M, LANDEWE R, Van Der HEIJDE D, LISTING J, BRANDT J, BRAUN J, BURGOS-VARGAS R, COLLANTES-ESTEVEZ E, DAVIS J, DIJKMANS B, DOUGADOS M, EMERY P, Van Der HORST-BRUINSMA IE, INMAN R, KHAN MA, LEIRISALO-REPO M, Van Der LINDEN S, MAKSYMOWYCH WP, MIELANTS H, OLIVIERI I, STURROCK R, De VLAM K, SIEPER J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770–776. doi: 10.1136/ard.2009.108217. PubMed DOI

SACHDEVA M, MO YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2010;2:170–180. PubMed PMC

SIEPER J, PODDUBNYY D. Axial spondyloarthritis. Lancet. 2017;390:73–84. doi: 10.1016/S0140-6736(16)31591-4. PubMed DOI

TAUROG JD, CHHABRA A, COLBERT RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;375:1303. doi: 10.1056/NEJMc1609622. PubMed DOI

Van Der LINDEN S, VALKENBURG HA, CATS A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–368. doi: 10.1002/art.1780270401. PubMed DOI

WATAD A, BRIDGEWOOD C, RUSSELL T, MARZO-ORTEGA H, CUTHBERT R, McGONAGLE D. The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol. 2018;9:2668. doi: 10.3389/fimmu.2018.02668. PubMed DOI PMC

YANG B, GUO H, ZHANG Y, CHEN L, YING D, DONG S. MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PLoS One. 2011;6:e21679. doi: 10.1371/journal.pone.0021679. PubMed DOI PMC

Is there a potential of circulating miRNAs as biomarkers in rheumatic diseases?